Stroke :脑中风,阿司匹林治疗失败,有哪些抗血栓方案?

2021-11-02 Freeman MedSci原创

这些发现强调了未来研究的必要性,以确定这种非常常见和复杂的临床情况的最佳管理策略。

在美国,超过40%的70岁以上的成年人服用阿司匹林进行血管疾病的初级预防,超过70%的有心血管疾病史的任何年龄的患者每天服用阿司匹林。

虽然阿司匹林常用于心血管疾病和中风的预防,但许多服用阿司匹林单一疗法的患者仍会出现缺血性中风(所谓的阿司匹林失效)。尽管经常考虑增加阿司匹林的剂量,增加第二种药物,或改用另一种抗血小板药物,但没有证据表明这些方法有什么优越性。

藉此, University of Texas Southwestern Medical Center的Jay B. Lusk等人,评估了急性缺血性卒中老年患者中阿司匹林失效的发生率,并描述了他们出院时为二级卒中预防而进行的抗栓治疗的处方模式。

他们使用美国心脏协会Get With The Guidelines Stroke Registry的数据来描述2012年10月至2017年12月期间美国1734家医院的缺血性卒中联邦医疗保险受益人的出院抗血栓治疗模式,这些受益人在卒中前服用阿司匹林,并活着出院。

在261名缺血性卒中幸存者中,有100 016人(38.2%)在卒中前服用阿司匹林单药治疗。其中,44.4%的患者在出院时仍服用阿司匹林单药治疗(20.9%为81毫克,18.2%为325毫克,5.3%为其他或未知剂量)。

接下来最常见的治疗选择是双重抗血小板治疗(24.6%),其次是氯吡格雷单药治疗(17.8%)。

其余13.2%的患者出院时使用阿司匹林/双嘧达莫、华法林或非维生素K拮抗剂的口服抗凝剂,同时使用或不使用抗血小板,或根本没有抗血栓治疗。

这个研究的重要意义在于发现:在接受阿司匹林预防治疗的缺血性卒中患者中,近一半的患者出院后接受阿司匹林单药治疗,没有改变抗血栓类药物,而另一半患者出院后接受氯吡格雷单药治疗、双重抗血小板治疗或其他不常用药物。

这些发现强调了未来研究的必要性,以确定这种非常常见和复杂的临床情况的最佳管理策略。


原文出处:
Lusk JB, Xu H, Peterson ED, et al. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke. Published online October 27, 2021:STROKEAHA.121.034622. doi:10.1161/STROKEAHA.121.034622

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1195034, encodeId=273611950343b, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sat Feb 19 11:15:30 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717311, encodeId=e20a1e17311bb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64603, encryptionId=e3436460313, topicName=治疗失败)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1c332383811, createdName=ligang4450, createdTime=Thu Dec 16 22:43:23 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574144, encodeId=7f6915e414451, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Nov 03 21:43:23 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066480, encodeId=2ae11066480c5, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb65256110, createdName=lishuns, createdTime=Wed Nov 03 08:06:54 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1195034, encodeId=273611950343b, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sat Feb 19 11:15:30 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717311, encodeId=e20a1e17311bb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64603, encryptionId=e3436460313, topicName=治疗失败)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1c332383811, createdName=ligang4450, createdTime=Thu Dec 16 22:43:23 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574144, encodeId=7f6915e414451, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Nov 03 21:43:23 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066480, encodeId=2ae11066480c5, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb65256110, createdName=lishuns, createdTime=Wed Nov 03 08:06:54 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1195034, encodeId=273611950343b, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sat Feb 19 11:15:30 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717311, encodeId=e20a1e17311bb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64603, encryptionId=e3436460313, topicName=治疗失败)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1c332383811, createdName=ligang4450, createdTime=Thu Dec 16 22:43:23 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574144, encodeId=7f6915e414451, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Nov 03 21:43:23 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066480, encodeId=2ae11066480c5, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb65256110, createdName=lishuns, createdTime=Wed Nov 03 08:06:54 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 gwc388
  4. [GetPortalCommentsPageByObjectIdResponse(id=1195034, encodeId=273611950343b, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Sat Feb 19 11:15:30 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717311, encodeId=e20a1e17311bb, content=<a href='/topic/show?id=e3436460313' target=_blank style='color:#2F92EE;'>#治疗失败#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64603, encryptionId=e3436460313, topicName=治疗失败)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1c332383811, createdName=ligang4450, createdTime=Thu Dec 16 22:43:23 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574144, encodeId=7f6915e414451, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Nov 03 21:43:23 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066480, encodeId=2ae11066480c5, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2eb65256110, createdName=lishuns, createdTime=Wed Nov 03 08:06:54 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 lishuns

    学习学习学习

    0

相关威廉亚洲官网

Neurology :150万人脑中风,取栓和溶栓者,都有哪些特点?

从2016年到2018年,美国IS的tPA和EVT的使用率有所上升

Stroke:血栓切除术的并发症率不容忽视

血栓切除术的并发症率是不可忽视的,ENT最常见

Neurology :脑中风临床试验,女性患者纳入数量或过少

相对于人口中的疾病负担,女性在卒中试验中的代表比例过低。

Neurology:脑中风,CT低灌注-低密度区,有利于发现4.5小时内的脑中风患者

急性缺血性卒中患者,,CT低灌注-低密度区很可能是在溶栓治疗的时间窗内

Neurology : 脑中风后,考虑缺血半影区,有利于预测病人预后

考虑到基线时,有大面积梗死核心的、低灌注组织的功能恢复,可以更精确地估计治疗的预期效益。

Stroke:10年随访:短暂性脑缺血发作和轻微中风后紧急二级预防的长期意义如何

短期内对短暂性脑缺血发作/轻微脑卒中的其他有效急性治疗也将有可能产生长期效益。

拓展阅读

脑梗死、脑出血、脑卒中、脑中风是一回事儿吗?

脑死.脑出血.脑卒中.脑中风,鉴别,解析。

STROKE:中国学者:坐姿太极拳来啦,能为中风患者提供更有效的功能恢复!

研究结果支持量身定制的坐姿太极拳项目对改善亚急性中风幸存者的康复效果

stroke:家族患蛛网膜下腔出血,新评分可辅助预测个人SAH风险

对于有≥2个受影响的一级亲属的人,NASH评分改善了目前的预测

Stroke:血管内治疗,美国黑人和白人是否有区别?

血管内治疗(EVT)对选定的大血管闭塞(LVO)急性缺血性卒中(AIS)患者来说是一种非常有影响的治疗方法。

Stroke:多模态神经影像和行为数据,可预测脑中风语言康复治疗

中风后静止状态下的大脑功能连接是预测治疗反应性的一个特别重要的因素

Stroke:伴房颤的虚弱患者,抗凝治疗预后更好

在体弱的房颤患者中,OAC治疗与积极的净临床结果有关